{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:34:45Z","timestamp":1762508085189,"version":"3.37.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Standard bone marrow biopsy (BMB) and bone involvement with follicular lymphoma (FL) on positron emission tomography (PET)\/computed tomography (CT) both predict early clinical failure in FL. The key clinical question is whether PET\/CT findings can obviate the need for BMB. The goal of this study was to determine the value of PET\/CT in determining bone involvement in FL, using posterior iliac crest BMB as the gold standard.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A total of 548 patients with newly diagnosed grade 1\u20133A FL were included. The presence, pattern, and location of bone involvement, spleen involvement, and standardized uptake values (SUVs) in the L3 vertebral body were recorded for all patients and compared with the BMB report.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Excluding patients with focal bone lesions on PET\/CT, the sensitivity and specificity of PET\/CT in detecting bone or marrow involvement, compared with BMB, were 53% and 88%, respectively. The sensitivity and specificity of spleen involvement on PET\/CT in predicting a positive BMB were 55% and 86%, respectively. An L3 SUVmax of less than 2.0 resulted in a negative predictive value (NPV) of 96% for marrow involvement on BMB; an L3 SUVmean below 1.4 resulted in an NPV of 100%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In newly diagnosed FL, PET\/CT-detected bone and splenic involvement is highly specific for a positive BMB, and very low SUV values (&amp;lt;2.0 SUVmax and &amp;lt;\u20091.4 SUVmean) in the lumbar spine have a high NPV for a negative BMB. Routine BMB may be obviated in these patients. BMB remains necessary to definitively exclude bone marrow involvement in a large majority of patients with a negative PET.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice<\/jats:title><jats:p>Predicting early clinical failure in follicular lymphoma (FL) is important but difficult. Bone marrow involvement by FL is associated with early clinical failure, and determining this involvement is a key component of the initial staging. This study highlights that in certain patients, positron emission tomography\/computed tomography is sufficient in determining bone or marrow involvement, without the need for a confirmatory bone marrow biopsy (BMB). An algorithm is provided based on these findings to help clinicians determine which patients would benefit from BMB and when it can be avoided.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0952","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T12:23:24Z","timestamp":1587558204000},"page":"689-695","source":"Crossref","is-referenced-by-count":11,"title":["Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma"],"prefix":"10.1093","volume":"25","author":[{"given":"Fr\u00e9d\u00e9rique","family":"St-Pierre","sequence":"first","affiliation":[{"name":"Department\u2009of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Broski","sequence":"additional","affiliation":[{"name":"Department\u2009of Radiology, Division\u2009of Nuclear Radiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy R.","family":"LaPlant","sequence":"additional","affiliation":[{"name":"Department\u2009of Health Sciences Research, Division\u2009of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department\u2009of Health Sciences Research, Division\u2009of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Ristow","sequence":"additional","affiliation":[{"name":"Department\u2009of Medicine, Division\u2009of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gita","family":"Thanarajasingam","sequence":"additional","affiliation":[{"name":"Department\u2009of Medicine, Division\u2009of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Macon","sequence":"additional","affiliation":[{"name":"Department\u2009of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Department\u2009of Medicine, Division\u2009of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Department\u2009of Medicine, Division\u2009of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"2021122510522337400_onco13325-bib-0001","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of french and us cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510522337400_onco13325-bib-0002","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.clml.2016.08.011","article-title":"Indolent lymphomas that present with clinically aggressive features: A subset of low-grade lymphomas with a behavior inconsistent with the histologic diagnosis","volume":"16","author":"Cabanillas","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122510522337400_onco13325-bib-0003","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"2021122510522337400_onco13325-bib-0004","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122510522337400_onco13325-bib-0005","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: Evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"key":"2021122510522337400_onco13325-bib-0006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigue","year":"2018","journal-title":"Ann Hematol"},{"key":"2021122510522337400_onco13325-bib-0007","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"2021122510522337400_onco13325-bib-0008","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122510522337400_onco13325-bib-0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"2021122510522337400_onco13325-bib-0010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ajh.25493","article-title":"Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma","volume":"94","author":"St-Pierre","year":"2019","journal-title":"Am J Hematol"},{"key":"2021122510522337400_onco13325-bib-0011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14071","article-title":"(18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma","volume":"174","author":"Ujjani","year":"2016","journal-title":"Br J Haematol"},{"key":"2021122510522337400_onco13325-bib-0012","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1177\/0284185117701305","article-title":"Use of FDG PET\/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: Comparison with iliac crest bone marrow biopsy","volume":"58","author":"Teagle","year":"2017","journal-title":"Acta Radiologica"},{"key":"2021122510522337400_onco13325-bib-0013","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.blre.2015.06.003","article-title":"Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma","volume":"29","author":"Adams","year":"2015","journal-title":"Blood Rev"},{"key":"2021122510522337400_onco13325-bib-0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"key":"2021122510522337400_onco13325-bib-0015","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdt533","article-title":"Systematic review and meta-analysis on the diagnostic performance of FDG-PET\/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: Is bone marrow biopsy still necessary?","volume":"25","author":"Adams","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122510522337400_onco13325-bib-0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5603\/NMR.2016.0029","article-title":"18F-FDG PET\/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): A clinical case with a literature review","volume":"19","author":"Chaushev","year":"2016","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"2021122510522337400_onco13325-bib-0017","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122510522337400_onco13325-bib-0018","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana;infomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122510522337400_onco13325-bib-0019","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122510522337400_onco13325-bib-0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading","volume":"17","author":"Wohrer","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122510522337400_onco13325-bib-0021","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002910","article-title":"The value of PET\/CT in detecting bone marrow involvement in patients with follicular lymphoma","volume":"95","author":"Perry","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2021122510522337400_onco13325-bib-0022","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MNM.0000000000000059","article-title":"The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma","volume":"35","author":"El-Najjar","year":"2014","journal-title":"Nucl Med Commun"},{"key":"2021122510522337400_onco13325-bib-0023","first-page":"1331","article-title":"Prognostic value of maximum standard uptake on pretreatment 18F-FDG PET\/CT scan in newly diagnosed follicular lymphoma [in Chinese]","volume":"23","author":"Ding","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0952","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0952","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0952","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/8\/689\/41920389\/oncolo_25_8_689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/8\/689\/41920389\/oncolo_25_8_689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T06:36:07Z","timestamp":1696055767000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/8\/689\/6443906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,28]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0952","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2020,8,1]]},"published":{"date-parts":[[2020,4,28]]}}}